Streetbeat News

Products Services

ABVC

ABVC BioPharma has completed subject recruitment for an interim analysis on its ADHD Phase IIb clinical study. The study involves approximately 100 patients in the US and Taiwan. The Phase IIb study continues the Phase IIa study of ABV-1505, which achieved its primary endpoints and was accepted by the FDA in October 2020. The global ADHD treatment market is expected to reach $32.14 billion by 2030.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 12:41 pm

KA

Kineta, Inc. (NASDAQ:KA) has announced the first patient dosing in Part B of its Phase 1/2 VISTA-101 clinical trial. The trial will evaluate the safety and tolerability of Kineta's VISTA blocking immunotherapy, KVA12123, in combination with Merck's anti-PD-1 therapy KEYTRUDA in patients with advanced solid tumors. Initial combination therapy clinical data is expected in Q2 2024.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 12:40 pm

AAPL

BTCUSD

TSLA

The article covers a range of topics including US politics, world politics, Israel-Hamas conflict, tech, electric vehicles, consumer, communication, and space. Key highlights include Tesla's recall of nearly 55,000 Model X, a crypto whale losing $49K in 10 minutes due to Bitcoin ETF rumors, and Biden's planned visit to Israel. Other notable mentions include Apple's resilience in the global smartphone market, Rolls-Royce's plan to cut up to 2,500 jobs, and Netflix's intensified foray into gaming.

Portfolio Pulse from Akanksha Bakshi

October 17, 2023 | 12:37 pm

HCA

ILMN

HCA Healthcare, Inc. (NYSE:HCA) and GRAIL, LLC have announced a strategic collaboration to advance comprehensive cancer care through early detection. GRAIL's Galleri multi-cancer early detection (MCED) test will be available to patients who meet screening criteria at select HCA Healthcare physician practices. The Galleri test can detect a shared cancer signal across more than 50 types of cancers using a simple blood draw. HCA Healthcare is also participating in the PATHFINDER 2 multi-center interventional study of the Galleri test.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 12:37 pm

GRI

Biotechnology company GRI Bio, Inc. (NASDAQ:GRI) has announced a partnership with the UK's National Institute for Health and Care Research Respiratory Translational Research Collaboration (NIHR Respiratory TRC) to advance its NKT regulation technology for the treatment of inflammatory, fibrotic, and autoimmune diseases. The collaboration will provide GRI Bio with additional data on the role of NKT cells in idiopathic pulmonary fibrosis (IPF) from UK patients. GRI Bio's lead program, GRI-0621, has shown promise in improving fibrosis in multiple disease models and improving liver function tests and other markers of inflammation and injury in patients.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 12:36 pm

AIR

AAR Corp. (NYSE:AIR) has extended its contract with MTU Maintenance to supply parts for Pratt & Whitney PW2000 engines. This marks the fourth extension of a contract that began in 2009. The partnership streamlines logistical processes and creates cost efficiencies for MTU Maintenance's customers.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 12:35 pm

NRSN

Neurosense Therapeutics Ltd is set to enroll its first patient in a Phase 2 Alzheimer's Disease study in the coming weeks. The company is fully funded into Q2 2024 and expects results from its Clinical Phase 2b ALS study in Q4 2023.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 12:35 pm

GMDA

Gamida Cell Ltd (NASDAQ:GMDA) has released early data from an ongoing Phase 1 study of its natural killer (NK) cell therapy candidate GDA-201, showing encouraging anti-tumor activity in heavily pretreated patients with CD20-positive non-Hodgkin lymphoma. Preliminary results showed marked shrinkage of target lesions in five patients. No dose-limiting toxicities were reported. The company's shares are up 6.01% at $0.94 during the premarket session.

Portfolio Pulse from Vandana Singh

October 17, 2023 | 12:34 pm

BMEA

Biomea Fusion has announced the first patient dosing of its covalent FLT3 inhibitor, BMF-500, in a Phase I clinical trial for relapsed or refractory acute leukemia. The drug, developed using Biomea's proprietary FUSION™ System, is designed to be highly selective for FLT3 and avoid inhibition of closely related receptors. Preclinical studies have shown promising activity against all known FLT3 activating and resistance conferring mutations.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 12:34 pm

DDD

3D Systems (NYSE:DDD) has announced that its point-of-care additive manufacturing technologies have been used to produce patient-specific 3D-printed cranial implants for surgeries at University Hospital Basel (Switzerland) and Salzburg University Hospital (Austria). The implants, made from Polyetheretherketone (PEEK) material, were created using 3D Systems' unique extrusion printing technology. The cranial implants market is expected to reach over $2 billion by 2030.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 12:34 pm